Hong Kong Gas Utilities Stock News

Amidst global concerns about AI disruption and fluctuating economic indicators, Asian markets have shown resilience with Japan's stock indices rising sharply and Chinese stocks edging higher as the Lunar New Year approaches. In this environment, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential market inefficiencies.

Key Insights Significant insider control over China Cultural Tourism and Agriculture Group implies vested interests in...

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...

Most readers would already be aware that Logory Logistics Technology's (HKG:2482) stock increased significantly by 15...

Key Insights Jia Yao Holdings' significant insider ownership suggests inherent interests in company's expansion The...

Unfortunately for some shareholders, the JW (Cayman) Therapeutics Co. Ltd ( HKG:2126 ) share price has dived 25% in the...

Langham Hospitality Investments Limited ( HKG:1270 ) shareholders have had their patience rewarded with a 29% share...

Despite the fact that Rainmed Medical Limited (HKG:2297) stock rose 12% last week, insiders who sold CN¥4.3m worth of...

Zhongshi Minan Holdings Limited ( HKG:8283 ) shareholders would be excited to see that the share price has had a great...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

As global markets grapple with AI disruption concerns and shifting economic indicators, Asian markets present unique opportunities for investors seeking growth in less saturated sectors. In this dynamic environment, identifying promising small-cap stocks requires a keen eye for companies that demonstrate resilience, innovation, and potential to thrive amid evolving market conditions.

As global markets grapple with concerns over AI disruption, Asian markets have shown resilience, with Japan's stock indices experiencing notable gains and Chinese stocks inching higher ahead of the Lunar New Year holidays. In such a landscape, penny stocks—often representing smaller or newer companies—remain an intriguing investment area despite being a somewhat outdated term. These stocks can offer unique growth opportunities at lower price points, particularly when they boast strong balance...

It is a pleasure to report that the Zero2IPO Holdings Inc. ( HKG:1945 ) is up 41% in the last quarter. But will that...

China Water Industry Group Limited ( HKG:1129 ) shareholders are no doubt pleased to see that the share price has...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Innovent Biologics (SEHK:1801) has caught investor attention after dosing the first participant in its pivotal Phase 3 HeriCare-Breast01 trial for IBI354, a HER2-directed antibody drug conjugate in breast cancer. See our latest analysis for Innovent Biologics. That Phase 3 milestone comes on the back of an eventful few weeks, including a new collaboration with Eli Lilly and strong 2025 product revenue figures. The share price has a year to date return of 13.07% alongside a 1 year total...

Shougang Fushan Resources Group (SEHK:639) issued 2025 earnings guidance, flagging profit of HK$600 million to HK$700 million, compared with HK$1,494 million in 2024, as lower clean coking coal prices weigh on results. See our latest analysis for Shougang Fushan Resources Group. The earnings guidance lands after a strong run for investors, with the latest share price at HK$3.34 and a 1 year total shareholder return of 53.95% alongside a 5 year total shareholder return of 194.16%. This...

Bright Smart Securities & Commodities Group (SEHK:1428) is set to join the Hang Seng Composite Index, with the change effective March 9, 2026. This inclusion also paves the way for Shanghai Hong Kong Stock Connect eligibility. See our latest analysis for Bright Smart Securities & Commodities Group. The upcoming index inclusion sits on top of a strong run, with a 90 day share price return of 25% and a 1 year total shareholder return of 247.33% pointing to building momentum rather than fading...

Alcohol partnership with Songhe puts Guoquan Food’s beverage plans in focus Guoquan Food (Shanghai) (SEHK:2517) has signed an alcoholic beverage procurement agreement with Songhe Group, tying drinks more tightly to its hot pot and barbecue offerings across more than 11,000 retail stores. See our latest analysis for Guoquan Food (Shanghai). The new alcohol deal lands after a strong 1 year total shareholder return of 119.77%, even though recent momentum has softened. The 7 day share price...

FDA clearance puts CS2009 in focus for CStone investors CStone Pharmaceuticals (SEHK:2616) said the U.S. FDA has cleared its IND for a Phase II trial of immunotherapy candidate CS2009 in advanced solid tumors, expanding an ongoing global multicenter study. See our latest analysis for CStone Pharmaceuticals. The FDA clearance comes as CStone’s share price sits at HK$5.91, with a 7 day share price return of 14.98% and a 1 year total shareholder return of 113.36%. This suggests momentum has...

SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000 reported for 2024. See our latest analysis for SSY Group. At a share price of HK$3.02, SSY Group has a modest 1-day share price return of a 0.33% decline, while its year-to-date share price return of 5.59% contrasts with a 3-year total shareholder return of a 28.75% decline. This suggests that...

China Medical System Holdings (SEHK:867) has drawn fresh attention after Chinese regulators cleared human trials for its CMS-D017 kidney disease therapy, alongside a new AI-focused drug discovery partnership with Insilico Medicine. See our latest analysis for China Medical System Holdings. The recent CMS D017 trial clearance and AI drug discovery tie up come as China Medical System Holdings’ share price sits at HK$15.33, with a 30 day share price return of 9.34% and a 1 year total shareholder...

Why Shanghai Henlius Biotech Is On Investors’ Radar Shanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and past 3 months, prompting a closer look at its fundamentals and returns. See our latest analysis for Shanghai Henlius Biotech. At the current share price of HK$70.5, Henlius has shown firm momentum, with a 10.5% 90 day share price return and a very large 1 year total shareholder return. Together, these figures...

InnoCare Pharma (SEHK:9969) has drawn fresh attention after dosing the first patient in a Phase II/III trial of its TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across several other dermatology indications. See our latest analysis for InnoCare Pharma. Despite the steady stream of trial updates and the recent IND approval for ICP-538, InnoCare Pharma’s 90 day share price return decline of 14.51% contrasts with a 1 year total shareholder return of 91.23%,...